The MoU establishes the foundation for a distribution and access agreement under which Orphan Therapies, a non-profit subsidiary of Orphan Therapeutics Accelerator (OTXL), would become the exclusive ...
Collaboration Aims to Establish Sustainable Access to a Newly Approved Therapy Targeting a Rare Immunodeficiency, Filling Urgent Gap Left by For-Profit Efforts CAMBRIDGE, Mass. and ROME, Dec. 15, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback